Țară: Statele Unite ale Americii
Limbă: engleză
Sursă: NLM (National Library of Medicine)
IDARUBICIN HYDROCHLORIDE (UNII: 5VV3MDU5IE) (IDARUBICIN - UNII:ZRP63D75JW)
Teva Parenteral Medicines, Inc.
IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE 1 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Idarubicin Hydrochloride Injection in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
Idarubicin Hydrochloride Injection, USP is a sterile, clear, orange-red, isotonic parenteral preservative-free solution for intravenous use only and is available as below: Contains no preservative. Discard unused portion. Store under refrigeration 2° to 8°C (36° to 46°F). Protect from light. Retain in carton until time of use.
Abbreviated New Drug Application
IDARUBICIN HYDROCHLORIDE- IDARUBICIN HYDROCHLORIDE INJECTION, SOLUTION TEVA PARENTERAL MEDICINES, INC. ---------- IDARUBICIN HYDROCHLORIDE INJECTION, USP RX ONLY FOR INTRAVENOUS USE ONLY WARNINGS 1. IDARUBICIN HYDROCHLORIDE INJECTION SHOULD BE GIVEN SLOWLY INTO A FREELY FLOWING INTRAVENOUS INFUSION. IT MUST NEVER BE GIVEN INTRAMUSCULARLY OR SUBCUTANEOUSLY. SEVERE LOCAL TISSUE NECROSIS CAN OCCUR IF THERE IS EXTRAVASATION DURING ADMINISTRATION. 2. AS IS THE CASE WITH OTHER ANTHRACYCLINES THE USE OF IDARUBICIN HYDROCHLORIDE INJECTION CAN CAUSE MYOCARDIAL TOXICITY LEADING TO CONGESTIVE HEART FAILURE. CARDIAC TOXICITY IS MORE COMMON IN PATIENTS WHO HAVE RECEIVED PRIOR ANTHRACYCLINES OR WHO HAVE PRE-EXISTING CARDIAC DISEASE. 3. AS IS USUAL WITH ANTILEUKEMIC AGENTS, SEVERE MYELOSUPPRESSION OCCURS WHEN IDARUBICIN HYDROCHLORIDE INJECTION IS USED AT EFFECTIVE THERAPEUTIC DOSES. 4. IT IS RECOMMENDED THAT IDARUBICIN HYDROCHLORIDE INJECTION BE ADMINISTERED ONLY UNDER THE SUPERVISION OF A PHYSICIAN WHO IS EXPERIENCED IN LEUKEMIA CHEMOTHERAPY AND IN FACILITIES WITH LABORATORY AND SUPPORTIVE RESOURCES ADEQUATE TO MONITOR DRUG TOLERANCE AND PROTECT AND MAINTAIN A PATIENT COMPROMISED BY DRUG TOXICITY. THE PHYSICIAN AND INSTITUTION MUST BE CAPABLE OF RESPONDING RAPIDLY AND COMPLETELY TO SEVERE HEMORRHAGIC CONDITIONS AND/OR OVERWHELMING INFECTION. 5. DOSAGE SHOULD BE REDUCED IN PATIENTS WITH IMPAIRED HEPATIC OR RENAL FUNCTION (SEE DOSAGE AND ADMINISTRATION). DESCRIPTION Idarubicin Hydrochloride Injection, USP contains idarubicin hydrochloride, USP and is a sterile, semi-synthetic, preservative-free solution (PFS) antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride, USP is 5, 12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-_lyxo_-hexopyranosyl)oxy]-7,8,9,10-tetrahydro- 6,9,11-trihydroxyhydrochloride, (7S-_cis_). The structural formula is as follows: C H NO •HCl M.W. 533.95 Idarubicin Hydrochloride Injection, USP is a sterile, clear, orange-red, isotonic parenteral preservative-free s Citiți documentul complet